Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration and option agreement with Shattuck Labs Inc. to generate bifunctional fusion proteins.
Valirx plc has signed an over-arching agreement with the University of Dundee and its drug discovery unit (DDU) to access research relating to novel therapeutic candidates.
Autolus Therapeutics Inc. has picked up plenty of financial momentum, about $600 million worth, in its runup to a November 2024 PDUFA date for its CD19 CAR T therapy. Helping propel that momentum is Biontech SE, another CAR T therapy developer. For $50 million cash, Biontech bought the rights to use Autolus’ manufacturing and commercial infrastructure in the U.K. so it can advance its CAR T-cell BNT-211 program in the clinic.
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. have announced a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
Aatec Medical GmbH has announced the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND), which will help advance the preclinical development of ATL-105.
Windtree Therapeutics Inc. has renewed its partnership with Chang Gung University to further research on SERCA2a, an important target for the company’s cardiovascular portfolio.
The European Chemicals Agency (ECHA) has contracted a consortium to conduct scientific studies on the reliability and relevance of new approach methodologies (NAMs) as alternatives to animal testing and to promote the use of such methods in the future.
Vaxxinity Inc. has announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.
RSS
